These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24759597)

  • 21. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
    Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J
    J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
    Copland M; Pellicano F; Richmond L; Allan EK; Hamilton A; Lee FY; Weinmann R; Holyoake TL
    Blood; 2008 Mar; 111(5):2843-53. PubMed ID: 18156496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
    Ma L; Shan Y; Bai R; Xue L; Eide CA; Ou J; Zhu LJ; Hutchinson L; Cerny J; Khoury HJ; Sheng Z; Druker BJ; Li S; Green MR
    Sci Transl Med; 2014 Sep; 6(252):252ra121. PubMed ID: 25186176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells].
    Liu YY; You LS; Qian WB; Tong Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):473-8. PubMed ID: 23086637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
    Ciarcia R; Damiano S; Montagnaro S; Pagnini U; Ruocco A; Caparrotti G; d'Angelo D; Boffo S; Morales F; Rizzolio F; Florio S; Giordano A
    Cell Cycle; 2013 Sep; 12(17):2839-48. PubMed ID: 23966159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
    Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
    PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.
    Chen X; Shi X; Zhao C; Li X; Lan X; Liu S; Huang H; Liu N; Liao S; Zang D; Song W; Liu Q; Carter BZ; Dou QP; Wang X; Liu J
    Oncotarget; 2014 Oct; 5(19):9118-32. PubMed ID: 25193854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia.
    Shao S; Li S; Qin Y; Wang X; Yang Y; Bai H; Zhou L; Zhao C; Wang C
    Int J Oncol; 2014 May; 44(5):1661-8. PubMed ID: 24585095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
    Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.
    Carew JS; Nawrocki ST; Kahue CN; Zhang H; Yang C; Chung L; Houghton JA; Huang P; Giles FJ; Cleveland JL
    Blood; 2007 Jul; 110(1):313-22. PubMed ID: 17363733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
    Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
    Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
    Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
    Carter BZ; Mak DH; Schober WD; Cabreira-Hansen M; Beran M; McQueen T; Chen W; Andreeff M
    Blood; 2006 Feb; 107(4):1555-63. PubMed ID: 16254145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
    Carter BZ; Mak DH; Shi Y; Schober WD; Wang RY; Konopleva M; Koller E; Dean NM; Andreeff M
    Cell Cycle; 2006 Oct; 5(19):2223-9. PubMed ID: 16969080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
    Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
    Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.